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OBJECTIVE: Nursing home residents with acute proxi-
mal deep-vein thrombosis (DVT) are usually transferred
to the hospital and treated initially with unfractionated
heparin administered by continuous infusion for five to
seven days. The anticoagulant response to this treatment
varies markedly among patients and therefore the dosage
must be adjusted by measuring the activated partial-
thromboplastin time closely. With the availability of low
molecular weight heparins and their proven efficacy and
safety in treatment and prophylaxis of deep vein throm-
bosis and no need to closely monitor any parameter and
adjust the dosage, it has become possible to treat DVT in
nursing home setting. We describe our findings of the eco-
nomic implications of two different therapies. METHOD:
All residents treated for DVT in the last 2 years were
identified and their charts reviewed as to the use of hep-
arin or enoxapirin (formulary LMWH in our institution).
Charts of 25 residents from each group matched for sex
and age were randomly reviewed as to efficacy, transfer
to hospital, days of hospitalization and costs of treat-
ment. RESULTS: The residents, in the heparin arm, were
transferred to the hospital, treated with continuous hep-
arin infusion, initiated on warfarin therapy and then
transferred back to the nursing home. The hospitalization
ranged from 5–15 days and the mean hospitalization cost
was $4196  225. Of the residents on enoxapirin arm,
only 9 residents were transferred to the hospital and the
hospitalization ranged from 3–5 days. The mean hospi-
talization and nursing home costs were $2258  150.
There was additional drug cost $490 in the heparin arm
and $800 in the of enoxapirin arm resulting in cost sav-
ing of $1628 per resident in the enoxapirin arm CON-
CLUSION: Our results indicate that enoxapirin is cost-
effective in the treatment of DVT in the nursing home
residents.
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INTRODUCTION: Noncompliance with lipid-lowering
medications has important implications for clinical and
economic outcomes of therapy. Little is known about
long-term utilization of HMG Co-A reductase inhibitors
(statins) because previous data have been based on
closely monitored trials or have observed patients for
short periods of time. OBJECTIVE: To describe patterns
and predictors of long-term compliance with statin ther-
apy in a US elderly population. METHODS: Cohort
study (n  607) of enrollees in the New Jersey Medicaid
and Pharmacy Assistance for the Aged and Disabled
(PAAD) programs aged 65 and older who began statin
therapy in the first half of 1990. Filled prescription data
were used to assess the proportion of days with any statin
available in each of 12 consecutive 6-month intervals af-
ter initiation of therapy. Demographic and clinical pre-
dictors of noncompliance, measured at baseline, were
identified using linear models for repeated measures. RE-
SULTS: Mean days with statin available was 64% in the
first 6 months of therapy and 45% in the next 6 months;
it then decreased linearly to 32% at the end of year 6.
The proportion of patients with 80% of days covered
was 41% in the first 6 months, 30% in the next 6
months, and 25% at the end of year 6. After controlling
for baseline demographic and clinical variables, lower
compliance in years 2 through 6 was significantly associ-
ated with duration of treatment, black race, lower in-
come, older age, and taking fewer other medications. By
contrast, first-year compliance was significantly better
among blacks than other races and age was not associ-
ated with utilization. CONCLUSIONS: Compliance with
statin therapy declines over time, with the greatest reduc-
tions occurring in the first year of treatment. Predictors
of short- and long-term compliance differ, with long-term
noncompliance most strongly predicted by age, race, and
socioeconomic status.
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INTRODUCTION: The purpose of this research is to
explore the relationship between the number of CHD
risk factors (RF) and duration of therapy of statins. CHD
risk factors play an important role in choice and goals of
lipid-lowering therapy. OBJECTIVE: To determine if the
median duration of therapy differs among Medicaid hy-
percholesteremic patients with 0,1,2 and 3 or greater
CHD risk factors who were treated with statins currently
on formulary. METHODS: Retrospective database anal-
ysis of pharmacy claims data for an intent-to-treat analy-
sis of Medicaid monotherapy statin patients. Patients
were required to be eligible 35 days before and 365 days
after the first statin prescription. New patients (n  767)
must have a 90 day washout period. Continuing patients
(n  1191) do not. The Medians test was used for non-
